Literature DB >> 27479232

MAIT be different-persisting dysfunction after DAA-mediated clearance of chronic hepatitis C virus infection.

Maike Hofmann1, Robert Thimme2.   

Abstract

MAIT cells are an abundant innate-like T-cell subset that is defined by the invariant T-cell receptor (iTCR) V-alpha chain Vα7.2-Jα33. Little is currently known about their frequency and function in chronic hepatitis C virus (HCV) infection and their fate after therapy-mediated HCV elimination by direct acting antivirals (DAA). In this issue of the European Journal of Immunology, Hengst et al. [Eur. J. Immunol. 2016. 46: 2204-2210] give important novel insights into the biological role of MAIT cells in a relevant human chronic viral infection by showing that first, MAIT cells are only present at low frequencies in chronic HCV infection; second, circulating MAIT cells in HCV patients also display an altered phenotype; third, they are impaired in their MR-1-dependent effector functions and finally, and maybe most importantly, MAIT-cell frequency and function was not restored after HCV elimination by DAA therapy. These results suggest that MAIT cells are severely affected by a chronic human viral infection in their frequency and function and that this impairment is not reversed after HCV elimination. This is in contrast to rapid DAA-mediated restorations of NK-cell and CD8(+) T-cell functions, and indicates a differential impact of chronic infection and clearance on different immune cell subsets.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  HCV; Immune responses; Inflammation; MAIT cells; T cells

Mesh:

Substances:

Year:  2016        PMID: 27479232     DOI: 10.1002/eji.201646581

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  3 in total

Review 1.  Current progress in host innate and adaptive immunity against hepatitis C virus infection.

Authors:  Jijing Shi; Yuanyuan Li; Wenxian Chang; Xuexiu Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2017-06-22       Impact factor: 6.047

2.  Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.

Authors:  Stefania Paolucci; Marta Premoli; Stefano Novati; Roberto Gulminetti; Renato Maserati; Giorgio Barbarini; Paolo Sacchi; Antonio Piralla; Davide Sassera; Leone De Marco; Alessia Girello; Mario U Mondelli; Fausto Baldanti
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

3.  Virus-Mediated Suppression of the Antigen Presentation Molecule MR1.

Authors:  Brian P McSharry; Carolyn Samer; Hamish E G McWilliam; Caroline L Ashley; Michael B Yee; Megan Steain; Ligong Liu; David P Fairlie; Paul R Kinchington; James McCluskey; Allison Abendroth; Jose A Villadangos; Jamie Rossjohn; Barry Slobedman
Journal:  Cell Rep       Date:  2020-03-03       Impact factor: 9.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.